CAS: 1299440-37-1 - Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
Formel:Unspecified
- Synonyme:
- Uplizna
- Inebilizumab-cdon
- Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
- Inebilizumab
- MEDI 551
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | Inebilizumab REF: TM-T76713CAS: 1299440-37-1 | SDS-PAGE:99.3%;SEC-HPLC:96.2% | 153,00 €~2.135,00 € | Di 03 Dez 24 |
 | Inebilizumab REF: 3D-CLA1393CAS: 1299440-37-1 | - - - | Nachfragen | Fr 13 Dez 24 |
Inebilizumab
CAS:1299440-37-1
Inebilizumab: humanized anti-CD19 antibody, enhances cytotoxicity against B cells, treats autoimmune diseases like MS.
Reinheit:
SDS-PAGE:99.3%;SEC-HPLC:96.2%
Farbe und Form:
Liquid
Molekulargewicht:
146.60 kDa
Ref: TM-T76713
| 1mg | 153,00 € | ||
| 5mg | 373,00 € | ||
| 10mg | 618,00 € | ||
| 25mg | 926,00 € | ||
| 50mg | 1.276,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 3. Dezember 2024
Inebilizumab
CAS:1299440-37-1
Anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cell.
Ref: 3D-CLA1393
| Unbestimmte Größe | Nachfragen |
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 13. Dezember 2024
